Search

Displaying results 3391 - 3400 of 10000 in total
  1. Drug

    Tauroursodeoxycholic acid

    go.drugbank.com/drugs/DB08834
    ApprovedInvestigationalWithdrawn

    [L17040] Due to a range of its molecular properties - namely its anti-apoptotic effects - tauroursodeoxycholic acid has been examined in inflammatory metabolic diseases and neurodegenerative diseases. … Tauroursodeoxycholic acid can reduce the absorption of cholesterol in the small intestine, thereby reducing the body's intake of dietary cholesterol and the body cholesterol content.

  2. Drug

    TMC-310911

    go.drugbank.com/drugs/DB15623
    Investigational

    [L12045,A191643] TMC-310911 is currently being investigated, in combination with other HIV therapies and antivirals, as a potential treatment for COVID-19 caused by SARS-CoV-2.[L12012] … TMC-310911 has shown marked activity against a variety of HIV-1 strains, including multi-PI-resistant strains, and may be less likely to generate resistance, making it a potentially desirable therapy for

  3. Drug

    Fenretinide

    go.drugbank.com/drugs/DB05076
    Investigational

    A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.

    Categories: Compounds used in a research, industrial, or household settingSynonyms: N-(4-hydroxyphenyl)all-trans retinamide
  4. Drug

    Valbenazine

    go.drugbank.com/drugs/DB11915
    ApprovedInvestigational

    [A261125] On August 2023, valbenazine was again approved by the FDA for the treatment of chorea associated with Huntington's disease respectively. … [A261165] On April 2017, valbenazine was approved by the FDA under the brand name INGREZZA as the first and only approved treatment for adults with Tardive Dyskinesia (TD).

  5. Drug

    Difamilast

    go.drugbank.com/drugs/DB14987
    ApprovedInvestigational

    of cytokines and chemokines [L55042]. … [L55042, A275424, A275420] As difamilast's mechanism of action involves the inhibition of PDE4, the inhibition leads to an increase in intracellular cyclic AMP and a subsequent decrease in the production

  6. Indication

    Obstructive Sleep Apnea (OSA)

    go.drugbank.com/conditions/DBCOND0040865
    Drugs: Modafinil
    Synonyms: Obstructive Sleep Apnea (SAOS)
  7. Drug

    Anileridine

    go.drugbank.com/drugs/DB00913
    ApprovedIllicitWithdrawn

    Narcotic analgesics act in the central nervous system (CNS) to relieve pain. Some of their side effects are also caused by actions in the CNS.

    Synonyms: N-β-(p-aminophenyl)ethylnormeperidine, N-(β-(p-aminophenyl)ethyl)-4-phenyl-4-carbethoxypiperidine
  8. Drug

    Catridecacog

    go.drugbank.com/drugs/DB09310
    Approved

    Coagulation Factor XIII A-Subunit (Recombinant) is available in the US as the commmercially available product Tretten, and in the EU as NovoThirteen. … For people with congenital deficiency or mutation of Factor XIII, a rare bleeding disorder, exogenous replacement of this key coagulation factor is essential for management and prevention of bleeding episodes

  9. Drug

    Nogalamycin

    go.drugbank.com/drugs/DB20882
    Experimental

    The usage of the INN stem '-mycin' in the name indicates that Nogalamycin is a antibiotic, produced by Streptomyces strain. Nogalamycin has a monoisotopic molecular weight of 787.31 Da.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Desirudin

    go.drugbank.com/drugs/DB11095
    ApprovedWithdrawn

    Desirudin is a direct inhibitor of human thrombin. … Hirudin is a single polypeptide chain of 65 amino acids residues and contains three disulfide bridges. Desirudin has a chemical formula of C287H440N80O110S6 with a molecular weight of 6963.52.